Renowned microbiologist will bring clinical expertise as the company advances its platform for rapid pathogen identification and antibiotic susceptibility testing AUSTIN, Texas — March 10, 2022 — Pattern Bioscience, Inc., developer of Digital Culture™ technology for...
AUSTIN, Texas, December 8, 2021 – Pattern Bioscience, Inc. has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Pneumonia Action Panel. The test uses Pattern’s Digital CultureTM technology to provide a fast and...
Led by Illumina Ventures, the Series B-1 round will accelerate development and validation of transformational bacterial testing technology AUSTIN, Texas, July 14, 2020 – Pattern Bioscience, Inc. today announced $9M in additional funding to accelerate the development...
$6.8M CARB-X award plus $6.4M Series B led by Omnimed will help bring new technology to the fight against drug resistance. AUSTIN, Texas, February 4, 2020 – Pattern Bioscience, Inc., formerly operating as Klaris Diagnostics, today announced $13M in funding for the...
Klaris has been selected as a finalist in the AMR Diagnostics Challenge federal prize competition, and will receive $100,000 to further develop its rapid ID/AST technology. The Challenge is a joint effort between the National Institutes of Health and the HHS Office...
Series A Financing Led by Omnimed Capital Austin, Texas, May 17, 2018 – Klaris Diagnostics, an in vitro diagnostics company focused on simplifying antibiotic selection for drug-resistant infections, today announced the completion of a $3.75 million Series...
